
Browsing restrictions can be lifted for a fee.
Bioptik Technology Incorporation engages in the production and sale of medical devices and reagents worldwide. It offers EasyMate blood glucose monitoring systems; blood glucose/cholesterol/uric acid monitoring systems and its strips; and hyaluronic acid skin care products. The company also provides skin care products and dietary supplements, as well as biodiesel products. Bioptik Technology Incorporation was founded in 1999 and is based in Zhunan, Taiwan.
4161
聿新科
-1.13%
(-0.01)
The most recent financial report for 聿新科 (4161) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4161's short-term business performance and financial health. For the latest updates on 4161's earnings releases, visit this page regularly.
According to historical valuation range analysis, 聿新科 (4161)'s current price-to-earnings (P/E) ratio is 18.65, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 聿新科 (4161) reported an Operating Profit of 9.19M with an Operating Margin of 4.27% this period, representing a decline of 59.05% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 聿新科 (4161) announced revenue of 215.16M, with a Year-Over-Year growth rate of 2.39%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 聿新科 (4161) held Total Cash and Cash Equivalents of 302.62M, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 聿新科 (4161) achieved the “three margins increasing” benchmark, with a gross margin of 26.42%%, operating margin of 4.27%%, and net margin of 12.01%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4161's profit trajectory and future growth potential.
According to the past four quarterly reports, 聿新科 (4161)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.45. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
聿新科 (4161)'s Free Cash Flow (FCF) for the period is 16.31M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 2,316% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.